Thyroid echogenicity in manic-depressive patients receiving lithium therapy

Area of Science:

• Endocrinology
• Psychiatry

Background:

• Lithium is a common treatment for manic-depressive disorder.
• Lithium use is associated with thyroid dysfunction, including hypothyroidism and changes in thyroid volume.
• The impact of lithium on thyroid echogenicity in euthyroid patients is not well understood.

Purpose of the Study:

• To investigate the effects of lithium therapy on thyroid volume and echogenicity in manic-depressive patients.
• To compare thyroid ultrasonography findings in lithium-treated patients with a control group of healthy volunteers.

Main Methods:

• Twenty manic-depressive patients on lithium therapy for at least 6 months and 20 age- and gender-matched euthyroid controls were studied.
• Thyroid function was assessed through laboratory measurements (FT4, TSH) and thyroid ultrasonography.
• Standardized grey scale analyses were performed on representative regions of interest (ROI) for echogenicity assessment.

Main Results:

• Thyroid function tests (FT4, TSH) and autoantibody levels were normal in both lithium-treated patients and controls.
• Lithium-treated patients exhibited significantly larger thyroid volumes compared to controls (16.9 vs. 11.4 ml).
• Thyroid echogenicity (grey scale units) was similar between the lithium group and the control group (23.9 vs. 24.2 GWE).

Conclusions:

• Lithium treatment leads to increased thyroid volume, potentially due to TSH upregulation secondary to subclinical thyroid function inhibition.
• Lithium does not appear to alter thyroid echogenicity in patients maintaining euthyroid status.
• Further research on echogenicity in lithium-induced overt hypothyroidism and autoimmune thyroid disease is warranted.